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Prostanoids have played a prominent role in the treatment of pulmonary arterial hypertension
(PAH). Several compounds and methods of administration have been studied: chronic
intravenously infused epoprostenol, chronic subcutaneously infused treprostinil, inhaled
iloprost, and oral beraprost. Chronic intravenous epoprostenol therapy has had a substantial
impact on the clinical management of patients with severe PAH. It improves exercise
capacity, hemodynamics, and survival in patients with idiopathic pulmonary arterial hyper-
tension (IPAH). It also improves exercise capacity and hemodynamics in patients with PAH
occurring in association with scleroderma. The complexity of epoprostenol therapy (chronic
indwelling catheters, reconstitution of the drug, operation of the infusion pump, and others)
has led to attempts to develop other prostanoids with simpler modes of delivery. Treprostinil,
a stable prostacyclin analogue with a half-life of 3 h, has been developed for subcutaneous
delivery. It has beneficial effects on exercise and hemodynamics, which depend somewhat on
the dose achieved. This, in turn, is determined by the patient’s ability to tolerate the drug’s
side effects, including pain and erythema at the infusion site. Inhaled iloprost therapy may
provide selectivity of the hemodynamic effects to the lung vasculature, thus avoiding systemic
side effects. In a randomized and controlled trial, iloprost resulted in improvement in a
combined end point incorporating the New York Heart Association functional class, 6-min
walk test, and deterioration or death. Beraprost is the first orally active prostacyclin analogue.
In the first of two randomized controlled trials, beraprost increased exercise capacity in
patients with IPAH, with no significant changes in subjects with associated conditions.
Hemodynamics did not change significantly, and no difference in survival was detected
between the two treatment groups. The second study showed that beraprost-treated patients
had less disease progression at six months and confirmed the results of the previous trial.
However, this improvement was no longer present at 9 or 12 months. In conclusion, though
treatment with prostanoids is complicated by their generally short half-lives and complicated
drug delivery systems, they continue to play an important role in the treatment of




















rmetabolite of arachidonic acid, prostacyclin is endog-
nously produced by vascular endothelium. It is a potent
asodilator in both the pulmonary and systemic circulations,
nd has antiplatelet aggregatory activity. A relative defi-
iency of prostacyclin may contribute to the pathogenesis of
ulmonary arterial hypertension (PAH). Clinical studies
ave explored the possibility that chronic therapy with
xogenous prostacyclin analogues might be of long-term
enefit in patients with moderately severe to severe PAH.
o date, the following compounds and methods of admin-
stration have been studied: chronic intravenously infused
poprostenol, chronic subcutaneously infused treprostinil,
nhaled iloprost, and oral beraprost. This report summarizes
he rationale for therapy utilizing each of these prostanoids,
nd it provides currently available evidence supporting the
se of each in the treatment of PAH.
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University of Michigan, Ann Arbor, Michigan; ‡University Hospital Gasthuisberg,
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lamart, France; and #Columbia University College of Physicians and Surgeons,
ew York, New York.aManuscript received November 26, 2003; accepted February 3, 2004.POPROSTENOL
ationale. Christman et al. (1) reported a deficiency of
rostacyclin and an excess of thromboxane in patients with
AH. Tuder et al. (2) showed decreased expression of
rostacyclin synthase in lungs from patients with severe
AH. Exogenously administered prostanoid analogues
ight help to overcome the adverse effects of decreased
ndogenously produced prostacyclin. Epoprostenol has a
ery short half-life in the bloodstream, requiring constant
ntravenous (IV) administration.
reatment. In a multicenter, randomized, controlled trial
n 81 patients with severe idiopathic pulmonary arterial
ypertension (IPAH, formerly known as primary pulmo-
ary hypertension or PPH), continuously intravenously
nfused epoprostenol plus conventional therapy (oral vaso-
ilators, anticoagulation, others) was compared to conven-
ional therapy alone. The epoprostenol-treated group dem-
nstrated improved survival and exercise tolerance,
ncreased cardiac output, and decreased pulmonary vascular
esistance (3). The beneficial effects of epoprostenol therapy
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June 16, 2004:56S–61S Prostanoid Therapy for PAHenefit in a small group of patients from centers involved in
he earliest clinical use of epoprostenol. Shapiro et al. (5)
nd McLaughlin et al. (6) have described sustained benefit
n larger numbers of patients. McLaughlin et al. (7) more
ecently reported experience with long-term epoprostenol
herapy in 162 consecutive patients with IPAH followed for
mean of 36.3 months (median, 31 months) (Fig. 1). Data
ollowed included functional class, exercise tolerance, and
emodynamics. Observed survival with epoprostenol ther-
py at one, two, and three years was 87.8%, 76.3%, and
2.8%, respectively, and was significantly greater than the
xpected survival of 58.9%, 46.3%, and 35.4%, respectively,
ased on historical data. Baseline predictors of survival
ncluded exercise tolerance, functional class, right atrial
ressure, and vasodilator response to adenosine. Predictors
f survival after the first year of therapy included functional
lass and improvement in exercise tolerance, cardiac index,
nd mean pulmonary artery pressure.
Sitbon et al. (8) evaluated the factors associated with
ong-term survival in patients with PPH/IPAH treated with
ontinuous epoprostenol infusion. A total of 178 patients in
ew York Heart Association (NYHA) functional class III
Abbreviations and Acronyms
IPAH  idiopathic pulmonary arterial hypertension
IV  intravenous
NO  nitric oxide
NYHA  New York Heart Association
PAH  pulmonary arterial hypertension
PPH  primary pulmonary hypertension
igure 1. McLauglin et al. (7) reported 162 consecutive patients diagnosed
ith primary pulmonary hypertension and treated with epoprostenol who
ere followed for a mean of 36.3 months (median, 31 months). Observed
urvival (diamonds) with epoprostenol therapy at one, two, and three years
as 87.8%, 76.3%, and 62.8%, respectively, and was significantly greater
han the expected survival (squares) of 58.9%, 46.3%, and 35.4%, respec-
ively, based on historical data. Baseline predictors of survival included
xercise tolerance, functional class, right atrial pressure, and vasodilator
esponse to adenosine. Predictors of survival after the first year of therapy
ncluded functional class and improvement in exercise tolerance, cardiac
ndex, and mean pulmonary artery pressure. Reprinted with permissionmrom Circulation (Lippincott Williams & Wilkins).r IV were treated with epoprostenol. Survival rates at one,
wo, three, and five years were 85%, 70%, 63%, and 55%,
espectively. Baseline variables associated with a poor out-
ome were a history of right-sided heart failure, NYHA
unctional class IV, 6-min walk test 250 m (median
alue), right atrial pressure12 mm Hg, and, paradoxically,
ean pulmonary artery pressure 65 mm Hg. Multivariate
nalysis, including both baseline variables and those mea-
ured after three months on epoprostenol, demonstrated
hat a history of right-sided heart failure, persistence of
YHA functional class III or IV at three months, and the
bsence of a decline in total pulmonary resistance of 30%,
elative to baseline, were associated with poor survival. The
nvestigators concluded that survival of patients with IPAH
reated with epoprostenol depends both on severity of
isease at baseline and the response to three months of
herapy.
A multicenter, randomized, and controlled study of
hronic IV epoprostenol in patients with PAH occurring in
ssociation with the scleroderma spectrum of disease
howed improvement in exercise capacity and hemodynam-
cs at 12 weeks as compared to the control group (9). Trends
ere seen toward greater improvement in severity of the
aynaud phenomenon and fewer new digital ulcers in the
poprostenol group. A survival difference between groups
as not seen in this population over the period of study, but
he study was not adequately powered to detect such a
ifference.
Epoprostenol therapy requires continuous IV infusion.
he drug has a very short half-life (6 min), is unstable at
cidic PpH, and cannot be taken orally. It is unstable at
oom temperature, and is generally kept cold prior to
nfusion. Patients are usually begun on a low dosage of
poprostenol (1 to 2 ng/kg/min), and gradually titrated
pward in increments of 1 to 2 ng/kg/min, based upon side
ffects and tolerance. Many patients seem to reach a
plateau” dose and may not require continued up-titration
rom that point. Whereas this dose may be between 20 and
0 ng/kg/min for many patients, the dose range is wide,
ith considerable interindividual variability.
Common side effects of epoprostenol therapy include
ushing, headache, jaw pain with the first bite of food,
which is usually tolerable), diarrhea, nausea, a blotchy
rythematous rash, and musculoskeletal aches and pain
predominantly involving the legs and feet). These side
ffects tend to be dose dependent, and they often respond to
cautious reduction in dose. Abrupt or inadvertent inter-
uption of the epoprostenol infusion should be avoided, as
his may lead to a rebound worsening of pulmonary hyper-
ension with symptomatic deterioration and perhaps even
eath. Complications of chronic IV therapy with epopro-
tenol include line-related infections (which range from exit
ite reactions, to tunnel infections and cellulitis, to bactere-
ia or sepsis), catheter-associated venous thrombosis,
hrombocytopenia, and ascites (although this may also be a
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Prostanoid Therapy for PAH June 16, 2004:56S–61SChronic IV epoprostenol therapy has had a substantial
mpact on the treatment of patients with moderately severe
o severe PAH. It has been best studied in patients with
PAH and PAH occurring in association with the sclero-
erma spectrum of disease. Because of the complexity of
poprostenol therapy (chronic indwelling catheters, recon-
titution of the drug, operation of the infusion pump, and so
orth), and the relative rarity of severe PAH, strong con-
ideration should be given to referral to centers of excel-
ence.
REPROSTINIL
ationale. Although epoprostenol is effective therapy for
AH, the nature of the delivery system has a number of
otential complications, which range in severity from local
xit site infections easily treated with oral antibiotics to
ife-threatening sepsis. Because of the short half-life of
poprostenol, interruptions in therapy related to catheter
isplacement or pump malfunction may be life-threatening.
are adverse events associated with the delivery system
nclude pneumothorax, deep venous thrombosis, and para-
oxical embolus. The efficacy of epoprostenol, coupled with
he limitations of the delivery system, has led to the
evelopment of prostacyclin analogues with alternative
outes of delivery. Treprostinil, a stable prostacyclin ana-
ogue with a half-life of 3 h, has been developed for
ubcutaneous delivery.
reatment. In 14 patients with IPAH, treatment acutely
ith IV epoprostenol and IV treprostinil had similar hemo-
ynamic effects (10). To test the alternative subcutaneous
elivery method, the effects of IV treprostinil and subcuta-
eous treprostinil were compared in 25 patients with IPAH.
cute hemodynamic effects were similar. An eight-week,
lacebo-controlled, 2:1 randomized trial of subcutaneous
reprostinil was subsequently performed in 26 patients with
PAH. An improvement of 37  17 m in the 6-min walk
istance occurred in patients receiving the active therapy
from 373 m to 411 m), compared to a 6  28-m reduction
n those receiving placebo (379 m vs. 384 m), a nonstatis-
ically significant trend. There was a favorable, but not
tatistically significant, trend in hemodynamics, with a 20%
eduction in pulmonary vascular resistance index over the
ight-week period in the group receiving active treprostinil.
dverse events including headache, diarrhea, flushing, jaw
ain, and foot pain were common in the treprostinil group,
imilar to what had been previously reported with epopro-
tenol. Pain (occasionally severe), erythema, and induration
t the site of the subcutaneous infusion occurred frequently.
A large international, placebo-controlled, randomized
tudy was conducted assessing the efficacy of chronic sub-
utaneously delivered treprostinil in patients with IPAH or
AH occurring in association with collagen vascular disease
r congenital systemic-to-pulmonary shunts (11). Four
undred-seventy patients enrolled between November 1998
nd October 1999 in 24 centers in North America and 16 senters in Europe, Australia, and Israel were randomly
ssigned to receive either continuous subcutaneously infused
reprostinil plus conventional therapy or continuous infu-
ion of placebo plus conventional therapy. Owing to the
nfusion-site pain and reaction that occurred in the proof-
f-concept trial, the dosing strategy called for lower doses at
nitiation, with a maximal allowable dose at the end of 12
eeks of 22.5 ng/kg/min. The primary end point was
xercise capacity as measured by the 6-min walk distance,
hich improved in the treprostinil group and was un-
hanged with placebo. The median difference between
reatment groups was 16 m (p  0.006), and the effect on
xercise tolerance appeared to be dose related. The patients
n the lowest two dosing quartiles experienced little im-
rovement in the 6-min walk distance, whereas patients in
he highest quartile in terms of dose (13.8 ng/kg/min)
emonstrated an improvement of 36 m. Treprostinil ther-
py was also associated with a significant improvement in
ean right atrial pressure, mean pulmonary artery pressure,
ardiac index, pulmonary vascular resistance, and mixed
enous oxygen saturation. Common side effects included
eadache, diarrhea, nausea, rash, jaw pain, and infusion-site
ain. Of the patients, 85% complained of pain at the
nfusion site, and 83% had erythema or induration at the
nfusion site. Although statistically significant, improve-
ent in the 6-min walk distance was relatively modest. The
easons for this may be multifactorial. Entry criteria for the
reprostinil trial were much more broad than for either of
he epoprostenol trials.
NHALED ILOPROST
ationale. Inhaled therapy for pulmonary hypertension
ay provide selectivity of the hemodynamic effects to the
ung vasculature, thus avoiding systemic side effects. Pul-
onary selective vasodilation has been described for inhaled
itric oxide (NO), but this agent has several drawbacks.
ost importantly, there are no data demonstrating im-
roved survival during therapy with inhaled NO, and this
gent possesses less vasodilative potency than do prostanoids
n IPAH patients (12,13). In contrast, prostacyclin (epopro-
tenol) has been shown to improve survival, exercise capac-
ty, and hemodynamics in patients with severe IPAH
3,4,6), and the continuous IV infusion of this drug has been
pproved for therapy in certain groups of patients in the
.S. and several European countries.
reatment. Iloprost is a prostacyclin analogue and has the
ame biologic profile as the natural substance with respect to
rostaglandin receptor binding and cellular effects (14). Its
ffects and its side effects are similar to those seen during
poprostenol infusion (15). In contrast, the chemical stabil-
ty of iloprost is considerably better. Where epoprostenol
as to be freshly dissolved, continuously cooled, and pro-
ected from light to provide full activity, iloprost is stable at
oom temperature, at pH 7.4, and normal light. Epopro-
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June 16, 2004:56S–61S Prostanoid Therapy for PAHerum half-life of 20 to 25 min (16). Iloprost has been
pproved for the treatment of PAH in New Zealand, and
as recently approved for the treatment of IPAH in
urope. Although epoprostenol is available in the United
tates and Europe, iloprost is not approved in the U.S.
Owing to the fact that the intra-acinar pulmonary arteries
re tightly surrounded by alveolar surfaces, it is possible to
asodilate these vessels by means of alveolar deposition of a
rostanoid. For long-term therapy, repetitive inhalations of
loprost are administered six to nine times daily. Each
nhalation requires 10 to 15 min. With alternative devices it
s possible to reduce the inhalation time to about 4 min (17)
nd to avoid any noise by use of ultrasound energy for
ebulization.
In patients with severe PAH, inhalation of aerosolized
loprost resulted in a substantial decrease in pulmonary
rtery pressure and resistance, concomitant with an increase
n cardiac output, in the absence of significant systemic
rtery pressure drop and ventilation–perfusion mismatch
18,19). In severe lung fibrosis, an increase of the pulmonary
hunt blood flow may limit the use of IV epoprostenol (19),
hereas inhaled iloprost can safely be administered. In
ncontrolled studies, inhaled iloprost was effective in de-
ompensated right heart failure (20) and showed favorable
ong-term hemodynamic improvement (21).
A large randomized, double-blind, placebo-controlled
uropean multicenter study with inhaled iloprost (Aerosol-
zed Iloprost Randomized, AIR [22]) involved a total of 203
atients in NYHA functional class III or class IV with
PAH or PAH occurring in association with appetite-
uppressant use, collagen vascular disease, or nonoperable
hromboembolic disease. In both the iloprost and placebo
roups, approximately 50% suffered from IPAH, and about
0% were in NYHA functional class III and 40% in NYHA
unctional class IV. The primary end point of the study,
efined as an improvement in NYHA functional class
ombined with at least 10% improvement in the 6-min
alking test, and no deterioration or death (combined
linical end point), was reached by 3.4  more patients in
he iloprost versus the placebo group (16.8% vs. 4.9%; p 
.007). This effect was achieved with a mean inhaled dose of
.37 ng/kg/min. In the 6-min walk test, the treatment effect
as 36.4 m in favor of iloprost (p  0.01). Hemodynamics
ignificantly deteriorated in the placebo group, whereas in
he iloprost group preinhalation values were unchanged
ompared to baseline, and postinhalation values were sig-
ificantly improved. Importantly, the number of patients
emaining on study medication, a measure corresponding to
vent-free survival, was significantly higher in the iloprost
han in the placebo group. Over three months of therapy,
here was no indication of tachyphylaxis. In the iloprost
roup, one patient (1.0%) died during the double-blind
tudy period versus four patients (4.0%) in the placebo
roup. Overall, the therapy was well tolerated. Cough
ccurred more frequently in the iloprost compared to the
lacebo group (38.6% vs. 25.5%) as well as headache (29.7% ns. 19.6%) and flushing (26.7% vs. 8.8%). These adverse
vents were mild and mostly transient. Syncope occurring in
he iloprost group was more often rated as serious than in
he placebo group, but was not commonly associated with
linical deterioration.
An open-label multicenter study of the two-year effects of
nhaled iloprost in pulmonary hypertension with an initial
hree-month controlled randomized phase was performed
n Germany. Inhaled iloprost treatment was administered
or up to two years to 63 patients (40 with IPAH and 23
ith PAH occurring in association with underlying disor-
ers). The median daily aerosolized dose was 100 g (total
nhaled dose 24 g) divided into six inhalations. At study
ntry, 66.6% of patients were in NYHA functional class III
r class IV, and 33.4% in functional class II. During the
wo-year study period, five IPAH patients were switched to
lternative therapy (mostly IV iloprost) but remained in the
tudy, and 13 patients discontinued the study prematurely (7
ith IPAH; 6 with other forms of PAH). After two years,
7 patients received inhaled iloprost treatment (25 with
PAH; 12 with other forms of PAH). During the course of
he study, eight patients died: three IPAH and five with
ther forms of PAH. Two of these patients died before
eceiving inhaled iloprost treatment. The survival rate ac-
ording to Kaplan-Meier analysis was 0.850 for all patients
nd 0.914 (95% confidence interval: 0.81; 1) for IPAH
atients for the two-year study period, including the ran-
omized phase. For IPAH patients, the predicted survival
ate according to D’Alonzo et al. (23) was 0.631, which
orresponds to 14.8 deaths. In contrast, only three IPAH
atients died. This suggests that survival on inhaled iloprost
reatment is substantially higher than expected.
In addition to treatment of IPAH, the pulmonary selec-
ivity of inhaled iloprost provides the opportunity to apply
rostanoids to patients who are prone to decrease in
ystemic arterial pressure, as in portopulmonary hyperten-
ion, and in emergency situations. The intrapulmonary
electivity also allows prostanoid application to patients who
re prone to intrapulmonary right to left shunt, like hepa-
opulmonary syndrome and lung fibrosis (19).
Inhaled iloprost may provide an alternative to the use of
V epoprostenol. When the clinical effects of inhaled
loprost and IV epoprostenol are compared, inhaled iloprost
as some advantages but also certain drawbacks. Most
mportantly, the inhalation provides potent pulmonary va-
odilation with little systemic side effects and no risk of
atheter complications. Additionally, it allows therapy in
atients with pre-existent ventilation-perfusion mismatch
nd in those who are prone to develop such a mismatch
uring systemic prostanoid application. The most important
rawback is the fact that the hemodynamic effect of inhaled
loprost plateaus within 30 to 90 min, and that six to nine
nhalations per day are needed to achieve satisfactory clinical
esults. Inhaled iloprost is currently approved in Europe for
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ationale. Beraprost is the first orally active prostacyclin
nalogue (24). It is rapidly absorbed during fasting, peak
oncentration is reached after 30 min, and the elimination
alf-life is 35 to 40 min after oral administration (25). In the
onocrotaline-induced pulmonary hypertension model,
eraprost has been shown to have a protective effect on the
evelopment of pulmonary hypertension lesions (26). High
oses of beraprost appear to have inotropic and chrono-
ropic effects in the isolated guinea pig myocardium (27).
eraprost has also been studied in peripheral vascular
iseases such as intermittent claudication (28), Raynaud
henomenon, and digital necrosis in systemic sclerosis (29),
ith variable results.
reatment. Beraprost has been used to treat PAH since
995 in Japan; several small open uncontrolled studies have
eported beneficial hemodynamic effects with beraprost in
atients with IPAH (24,30). Functional class also improved
n the majority of the patients after a mean of two months,
nd pulmonary vascular resistance was reduced by 26% (24,
0). Nagaya et al. (31), in a retrospective open uncontrolled
tudy, reported improved survival in 24 IPAH patients
reated with beraprost compared to a similar group of 34
atients on conventional therapy. The three-year survival
ate was 76% in the beraprost group and 44% in the
onventional-therapy group.
Two randomized, double-blind, placebo-controlled trials
f beraprost in PAH have been performed. The first was a
2-week double-blind, randomized, placebo-controlled trial
erformed in 130 NYHA functional class II and class III
atients with PAH of various etiologies (IPAH, and PAH
ssociated with collagen vascular diseases, congenital
ystemic-to-pulmonary shunts, portal hypertension, or hu-
an immunodeficiency virus infection) (32). At a median
ose of 80 g administered orally four times daily, beraprost
ncreased exercise capacity assessed by the 6-min walk test:
reatment effect was 25 m in the overall population, and
5 m in the IPAH patients, with no significant changes in
he exercise capacity of subjects with the associated condi-
ions. Hemodynamics had no statistically significant
hanges, and no difference in survival was detected between
he two treatment groups. Side effects related to systemic
asodilation were frequent, mainly in the initial titration
eriod.
A second trial evaluated the effects of beraprost therapy
or PAH in 116 NYHA functional class II and class III
atients. This study was 12 months in duration, double-
lind, randomized, and placebo-controlled (33). It showed
hat the beraprost-treated patients had less disease progres-
ion at six months and confirmed the results of the previous
rial (32): improved 6-min walk distance at three months
22 m from baseline) and six months (31 m), as
ompared to placebo. However, this improvement was no
onger present at 9 or 12 months (33). No significant
hanges occurred in hemodynamics or survival at month 12ersus baseline. It is possible that the beneficial effects of
eraprost may attenuate with time. Beraprost is approved
or treatment of PAH in Japan, and is currently under
valuation by the European Agency for the Evaluation of
edicinal Products (EMEA).
UMMARY
hronic IV epoprostenol therapy has had a substantial
mpact on the clinical management of patients with severe
AH. The complexity of epoprostenol therapy has led to
ttempts to develop other prostanoids with simpler modes
f delivery. Subcutaneous treprostinil, inhaled iloprost, and
ral beraprost have all been studied, and they have various
elative advantages and disadvantages. In conclusion, al-
hough treatment with prostanoids is complicated by their
enerally short half-lives and complicated drug-delivery
ystems, they continue to play an important role in the
reatment of PAH. Together with the other major classes of
herapeutic agents currently utilized or under investigation
or the treatment of PAH (including anticoagulants, sup-
lemental oxygen, calcium channel antagonists, endothelin
eceptor antagonists, phosphodiesterase inhibitors, and NO
r NO donors), prostanoids remain an important therapeu-
ic option.
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ivisions of Pulmonary Sciences and Critical Care Medicine, and
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